|
|
|
Translational research and demonstrating proof-of-concept turns intriguing scientific observations into clinically attractive and
commercially valuable assets. Only at that point will mainstream investors and commercially oriented partners begin to take notice
and open their deeper pockets to fund expensive late-stage development. Otherwise, important technologies languish in research labs,
never to see the light of day.
Several not-for-profit-disease organizations are at the forefront of innovative programs to de-risk research and development and
effectively collaborate with companies. Often referred to as "venture philanthropy", their contribution of disease insight,
experience, relationships, capital and credibility are central to achieving the ultimate goal for their patients,
to find a cure.
With a similar redefinition of their public mission underway, academic research institutions also seek more intimate and productive
collaborations through sponsored research, technology licensing and spinout companies.
These visionary organizations seek Health Advances' guidance in defining their commercially focused strategy using typical industry tools
such as portfolio prioritization, market forecasting, and technology valuation.
|
|
 |
|
|
|
|
|
 learn more
about our work with not-for-profit organizations.
|
|
|
|
|
 |
|
|
